Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer

NCT05273814 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Tislelizumab
DRUG: Pemetrexed
DRUG: Bevacizumab

Sponsor

Tianjin Medical University Cancer Institute and Hospital